Glycated hemoglobin A1c and cognitive impairment in complex chronic patients: A cross-sectional study.


  Vol. 45 (7-8) 2024 Neuro endocrinology letters Journal Article   2024; 45(7-8): 457-467 PubMed PMID:  39737496    Citation

OBJECTIVE: This study examines the relationship between Glycated hemoglobin A1c (HbA1c) levels and cognitive impairment in elderly patients with complex chronic conditions, a link previously unclear. DESIGN: This is a cross-sectional study. MATERIAL AND METHODS: The data from 2,366 patients in Catalonia (2013-2017) from the Dryad database. HbA1c levels were taken from clinical records, and cognitive function was assessed with ICD-10 criteria and the Pfeiffer test. We included demographic details, comorbidities, medications, and clinical data as covariates. Multivariate logistic regression was used, with subgroup analyses by age and other factors. RESULTS: The cohort had an average age of 84.1 ± 10 years; 46.4% were male, with an average HbA1c of 6.5 ± 1.4%. Cognitive impairment was present in 20.2% of participants. The association between HbA1c and cognitive impairment was not significant after adjusting for all variables (OR = 0.99, 95% CI: 0.91-1.08, p > 0.05). Ischemic cardiomyopathy (p = 0.008) and Barthel scores > 40 (p = 0.032) demonstrate an interaction effect on their relationship. CONCLUSION: In the population of patients with complex chronic conditions, HbA1c did not show a statistically significant correlation with cognitive impairment, indicating that HbA1c might not be an independent predictor of cognitive decline in this group, though further research is needed to confirm this.


 Full text PDF